|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||46.79|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen , announced Dysport® data will be presented today in two oral presentations at the annual meeting of the Association of Academic Physiatrists being held in Atlanta, February 13-17, 2018.
French pharma company Ipsen (IPN.PA) expects to bring more drugs to combat cancer, rare diseases and mobility impairment into its pipeline this year and has around one billion euros (888.29 million pounds) for asset purchases, its chief executive said. Ipsen's shares were up 10.03 percent at 1205 GMT, among top performers on the STOXX 600 (.STOXX) index. Ipsen Chief Executive David Meek told Reuters the company would continue to buy in new drugs which it could then take through its research and development channels and to the market.
Health Canada approves Ipsen's Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, , today announced that five new sub-analyses of the pivotal Phase 3 NAPOLI-1 trial will be presented at this year’s American Society of Clinical Oncology’s Gastrointestinal Cancer Symposium taking place in San Francisco, California, from January 18-20.
Exelixis, Inc. and Ipsen today announced detailed results of the pivotal phase 3 CELESTIAL trial in patients with previously treated advanced hepatocellular carcinoma , which will be presented in a late-breaking oral session at the 2018 ASCO-GI Symposium being held in San Francisco, January 18-20, 2018.
The former is used in combination with Roche’s Zelboraf as a treatment for advanced melanoma. Also, EXEL stock holders are looking at first-line approval for Cabometyx for hepatocellular carcinoma (a type of liver cancer) as potential for significant upside. EXEL retains marketing rights for Cabometyx in the U.S. and it has licensed marketing rights to Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) in Japan and France-based Ipsen S A/S ADR (OTCMKTS:IPSEY) outside the U.S. and Japan.
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen , today announced that five abstracts regarding Dysport® data have been accepted for poster presentations at the annual assembly of the American Academy of Physical Medicine and Rehabilitation on October 12-15, 2017 in Denver, Colorado.
Ipsen, a global biopharmaceutical company, today announced that it has joined the Pharmaceutical Research and Manufacturers of America , one of the most influential industry trade associations in the United States.
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen , today announced that four abstracts regarding Dysport® data have been accepted for poster presentations at the annual meeting of the Child Neurology Society on October 4-7, 2017 in Kansas City, Missouri.
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen , today announced that the U.S. Food and Drug Administration has approved a supplemental indication for Somatuline® Depot Injection 120 mg for the treatment of carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen , today announced a presentation of data from a retrospective study on managed Medicaid costs of treating children with Cerebral Palsy at the annual meeting of the American Academy of Cerebral Palsy and Developmental Medicine on September 13-16, 2017 in Montreal, Canada.